• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

在骨质疏松症高危患者中，特立帕肽治疗后的序贯治疗。

Sequential therapy following teriparatide treatment in patients at high risk of osteoporotic patients.

作者信息

Mori Satoshi

机构信息

Department of Bone and Joint Surgery, Osteoporosis Center, Seirei Hamamatsu General Hospital, Hamamatsu, Japan.

出版信息

J Bone Miner Metab. 2025 Jan;43(1):22-25. doi: 10.1007/s00774-025-01584-0. Epub 2025 Mar 22.

DOI:10.1007/s00774-025-01584-0
PMID:40119935
Abstract

The use of medications in sequence is recommended in several osteoporosis guidelines to afford the best protection for the patient at very high risk of fracture. Sequential therapy following once-weekly as well as daily teriparatide treatment is a potent option for those patients.

摘要

在多个骨质疏松症指南中，推荐序贯使用药物，以便为骨折高风险患者提供最佳保护。对于这些患者而言，在每周一次以及每日一次的特立帕肽治疗之后进行序贯治疗是一种有效的选择。

相似文献

1
Sequential therapy following teriparatide treatment in patients at high risk of osteoporotic patients.在骨质疏松症高危患者中，特立帕肽治疗后的序贯治疗。
J Bone Miner Metab. 2025 Jan;43(1):22-25. doi: 10.1007/s00774-025-01584-0. Epub 2025 Mar 22.
2
[Once-weekly teriparatide treatment on osteoporosis].[每周一次特立帕肽治疗骨质疏松症]
Clin Calcium. 2014 Jan;24(1):100-5.
3
[Daily subcutaneous injection of teriparatide : the progress and current issues].[特立帕肽每日皮下注射：进展与当前问题]
Clin Calcium. 2014 Jan;24(1):35-43.
4
Treatment responses with once-weekly teriparatide therapy for osteoporosis.每周一次特立帕肽治疗骨质疏松症的疗效
Osteoporos Int. 2016 Oct;27(10):3057-62. doi: 10.1007/s00198-016-3640-5. Epub 2016 May 27.
5
[The Importance of teriparatide in the treatment of osteoporosis].[特立帕肽在骨质疏松症治疗中的重要性]
Clin Calcium. 2016 Jun;26(6):905-13.
6
A systematic review on the use of daily subcutaneous administration of teriparatide for treatment of patients with osteoporosis at high risk for fracture in Asia.一项关于亚洲骨折高危骨质疏松症患者每日皮下注射特立帕肽治疗的系统评价。
Osteoporos Int. 2015 Jan;26(1):11-28. doi: 10.1007/s00198-014-2838-7. Epub 2014 Aug 20.
7
Safety and effectiveness of daily teriparatide for osteoporosis in patients with severe stages of chronic kidney disease: post hoc analysis of a postmarketing observational study.每日一次特立帕肽治疗重度慢性肾病患者骨质疏松症的安全性和有效性：一项上市后观察性研究的事后分析
Clin Interv Aging. 2016 Nov 15;11:1653-1659. doi: 10.2147/CIA.S120175. eCollection 2016.
8
Cost-effectiveness intervention thresholds for romosozumab and teriparatide in the treatment of osteoporosis in the UK.在英国，使用罗莫佐单抗和特立帕肽治疗骨质疏松症的成本效益干预阈值。
Osteoporos Int. 2024 Dec;35(12):2183-2193. doi: 10.1007/s00198-024-07251-w. Epub 2024 Oct 4.
9
Vertebral fracture risk after once-weekly teriparatide injections: follow-up study of Teriparatide Once-Weekly Efficacy Research (TOWER) trial.每周一次特立帕肽注射后的椎体骨折风险：特立帕肽每周一次疗效研究（TOWER）试验的随访研究。
Curr Med Res Opin. 2013 Mar;29(3):195-203. doi: 10.1185/03007995.2012.761956. Epub 2013 Jan 17.
10
Real-world safety and effectiveness of romosozumab following daily or weekly administration of teriparatide in primary and secondary osteoporosis.在原发性和继发性骨质疏松症患者中，每日或每周给予特立帕肽后，罗莫佐单抗的真实世界安全性和有效性。
Bone. 2025 Apr;193:117392. doi: 10.1016/j.bone.2025.117392. Epub 2025 Jan 16.

引用本文的文献

1
Thromboembolic and infectious complication risks in TKA and UKA: evidence from a Japanese nationwide cohort.全膝关节置换术和单髁膝关节置换术中的血栓栓塞和感染并发症风险：来自日本全国队列的证据。
Knee Surg Relat Res. 2025 May 8;37(1):19. doi: 10.1186/s43019-025-00273-6.

本文引用的文献

1
Sequential therapy with once-weekly teriparatide injection followed by alendronate versus monotherapy with alendronate alone in patients at high risk of osteoporotic fracture: final results of the Japanese Osteoporosis Intervention Trial-05.每周一次特立帕肽注射序贯治疗联合阿仑膦酸钠与单独使用阿仑膦酸钠治疗骨质疏松性骨折高风险患者的比较：日本骨质疏松干预试验-05 的最终结果。
Osteoporos Int. 2023 Jan;34(1):189-199. doi: 10.1007/s00198-022-06570-0. Epub 2022 Oct 14.
2
A randomized, controlled trial of once-weekly teriparatide injection versus alendronate in patients at high risk of osteoporotic fracture: primary results of the Japanese Osteoporosis Intervention Trial-05.一项每周一次特立帕肽注射与阿仑膦酸钠治疗骨质疏松性骨折高危患者的随机对照临床试验：日本骨质疏松干预试验-05 的主要结果。
Osteoporos Int. 2021 Nov;32(11):2301-2311. doi: 10.1007/s00198-021-05996-2. Epub 2021 May 17.
3
Development of the Asia Pacific Consortium on Osteoporosis (APCO) Framework: clinical standards of care for the screening, diagnosis, and management of osteoporosis in the Asia-Pacific region.亚太骨质疏松症联盟（APCO）框架的制定：亚太地区骨质疏松症筛查、诊断和管理的临床护理标准。
Osteoporos Int. 2021 Jul;32(7):1249-1275. doi: 10.1007/s00198-020-05742-0. Epub 2021 Jan 27.
4
Teriparatide Did Not Increase Adult Osteosarcoma Incidence in a 15-Year US Postmarketing Surveillance Study.特立帕肽在一项为期 15 年的美国上市后监测研究中未增加成人骨肉瘤的发病率。
J Bone Miner Res. 2021 Feb;36(2):244-251. doi: 10.1002/jbmr.4188. Epub 2020 Oct 13.
5
Assessing the incidence of osteosarcoma among teriparatide users based on Medicare Part D and US State Cancer Registry Data.基于医疗保险处方数据库和美国州癌症登记处数据评估特立帕肽使用者中骨肉瘤的发病率。
Pharmacoepidemiol Drug Saf. 2020 Dec;29(12):1616-1626. doi: 10.1002/pds.5103. Epub 2020 Sep 7.
6
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS/AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS- 2020 UPDATE .美国临床内分泌医师协会/美国内分泌学会 2020 年绝经后骨质疏松症诊断和治疗临床实践指南更新版
Endocr Pract. 2020 May;26(5):564-570. doi: 10.4158/GL-2020-0524.
7
Design of a randomized trial of teriparatide followed by alendronate: Japanese Osteoporosis Intervention Trial-05 (JOINT-05).特立帕肽序贯阿仑膦酸钠的随机临床试验设计：日本骨质疏松干预试验-05（JOINT-05）。
J Bone Miner Metab. 2020 May;38(3):412-417. doi: 10.1007/s00774-019-01074-0. Epub 2020 Jan 1.
8
Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society* Clinical Practice Guideline.绝经后妇女骨质疏松症的药物治疗：内分泌学会临床实践指南*。
J Clin Endocrinol Metab. 2019 May 1;104(5):1595-1622. doi: 10.1210/jc.2019-00221.
9
Reduction of Hip and Other Fractures in Patients Receiving Teriparatide in Real-World Clinical Practice: Integrated Analysis of Four Prospective Observational Studies.在真实临床实践中接受特立帕肽治疗的患者的髋部和其他骨折减少：四项前瞻性观察性研究的综合分析。
Calcif Tissue Int. 2019 Feb;104(2):193-200. doi: 10.1007/s00223-018-0485-2. Epub 2018 Oct 20.
10
European guidance for the diagnosis and management of osteoporosis in postmenopausal women.欧洲绝经后妇女骨质疏松症的诊断和管理指南。
Osteoporos Int. 2019 Jan;30(1):3-44. doi: 10.1007/s00198-018-4704-5. Epub 2018 Oct 15.